All News
Filter News
Found 808,890 articles
-
MedinCell: mdc-CWM Clinical Phase 3 Will Start In 2021
3/25/2021
MedinCell (Paris:MEDCL) confirms that late-stage clinical trials in patients receiving intra-articular mdc-CWM at the time of Total Knee Replacement (TKR) are planned as follows
-
Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions
3/25/2021
SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry and global expert in Type I molded glass, introduces an industry first offering of Type I molded glass vials.
-
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
3/25/2021
Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory (CSHL) virtual scientific meeting on Nucleic Acid Therapies.
-
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
3/25/2021
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”)
-
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of DirectorsRefreshed board to bring fresh perspectives, relevant expertise and diverse experience
3/25/2021
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of two new independent members to its Board of Directors with significant biotechnology and life sciences experience: Faith L. Charles, Partner, Corporate Transactions and Securities at Thompson Hine LLP and Mark Alvino, President at life sciences strategic advisory firm Hudson Square Capital LLC.
-
Isotopia Molecular Imaging and Molecular Targeting Technologies have signed a clinical supply agreement for Lu177 n.c.a.
3/25/2021
Isotopia Molecular Imaging is pleased to announce that it has begun a collaboration with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biopharmaceutical company, for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu) to support clinical development of its targeted radiotherapeutic products
-
Episode Six Enters the US Healthtech Market to Drive Digital Transformation and Payments Innovation
3/25/2021
Episode Six, the global provider of modern payment processing and banking infrastructure, announced its expansion into the U.S. healthtech market - a sector ripe for innovation with healthcare expenditure hitting nearly $3.7 trillion in 2018, per CMS projections.
-
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business Update
3/25/2021
- Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 - Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial - On Track to Report Multiple Milestones in 2021 Across Clinical-Stage Pipeline
-
Optimus HealthCare Services Completes Acquisition of AdhereRx, d/b/a PainScript
3/25/2021
Optimus Healthcare Services, Inc., announced that it has completed the acquisition of AdhereRx, d/b/a PainScript, a SaaS-based, Telehealth/Chronic Care Compliance platform company in a transaction valued at approximately $4,500,000 as of the market close on March 24, 2021.
-
FDA Grants Emergency Use Authorization to Tiger Tech's COVID screening device
3/25/2021
In a first of its kind approval, the FDA granted Emergency Use Authorization to Tiger Tech's COVID screening device.
-
Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
3/25/2021
WAKIX ® (pitolisant) Total Revenue of $160 Million for Full-Year 2020 ; $56 Million for Fourth Quarter 2020 Clinical Utility of WAKIX was Expanded with Additional Approval for Treatment of Cataplexy in Adults with Narcolepsy Enrollment Continues in Phase 2 Trial of Patients with Prader-Willi Syndrome On Track to Initiate Two Additional Clinical Trials with Pitolisant in 2021 Conference Call and Webcast to be Held Today at 8:30 a.m. ET
-
McKesson Approved as QCDR for 2021 MIPS Program Year
3/25/2021
For the fifth consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR)
-
Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
3/25/2021
Theralase® Technologies Inc. announced that Urology San Antonio has received site Institutional Review Board approval to commence a Pivotal Phase II Non-Muscle Invasive Bladder Cancer Clinical Study to enroll and treat patients with Bacillus Calmette Guerin-Unresponsive Carcinoma In-Situ or who are intolerant to BCG Therapy.
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
3/25/2021
Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer
-
Labcorp Lays out Priorities and Progress in Corporate Responsibility Report
3/25/2021
Company Focuses on Sustainable Environmental, Health and Safety Performance, and Advancing Diversity and Inclusion
-
Owlet’s Data Identifies Previously Undetected Increased Prevalence of Cardiac Arrhythmia in Young Infants in Study Published in The Journal of Pediatrics
3/25/2021
Owlet Baby Care Inc. announced today that a third-party study using data collected by its flagship product, the Owlet Smart Sock, identified that abnormally high heart rates – a condition known as a tachyarrhythmia – in infants are more common than existing clinical data has shown.
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
3/25/2021
– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 – Strong balance sheet enables significant optionality for growth and accelerated advancement of pipeline programs
-
Actinium Announces Completion of Enrollment of Second Dose Cohort in Actimab-A Venetoclax Combination Trial for Patients with R/R AML
3/25/2021
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) has been completed
-
IMV Appoints Kyle Kuvalanka to Board of Directors
3/25/2021
IMV to leverage Mr. Kuvalanka’s industry expertise as it advances its lead immunotherapy toward potential registration and commercialization
-
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
3/25/2021
Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2020.